“Side Effects”: Totally Depressing, but Not for the Reason You Think

Di Bonaventura Pictures

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


Side Effects
Di Bonaventura Pictures
106 minutes

If you walk into “Side Effects” looking for a gritty, realistic treatment of what it’s like to go on and off of psychiatric meds, you’re walking into the wrong theater. If you come looking for a critique of Big Pharma’s marketing practices, you’ll leave perplexed. But if you see “Side Effects” to get lost in Jude Law’s baby blue “trust-me” eyes and to indulge in Catherine Zeta-Jones’ skillful portrayal of a hyper-sexual psychiatrist in silky business casual, you’re definitely in the right place. Indeed, the film makes it easy enough to OD on psycho-thriller kitsch.

Steven Soderbergh’s latest (and possibly last) film in fact begins with a keen picture of deep-seated modern malaise. Emily Taylor, played by Rooney Mara, is a graphic designer in her late 20s—an artist with dreams deferred by her marriage to Martin (Channing Tatum), who’s just been let out of prison after serving time for insider trading. Emily finds herself overcome by crushing depression upon reuniting with Martin in the real world, and after a suicide attempt she finds herself in the care of Dr. Jonathan Banks (Jude Law), a warm, sentimental psychiatrist who consults Emily’s former shrink, played by Catherine Zeta-Jones, about treatment. Eventually, as recommended by Zeta-Jones’ character, Dr. Banks prescribes his patient Ablixa, a fictional SSRI with some very disturbing side effects. Or that’s what viewers are led to believe, until the second half of the film gets sucked into a senseless plot wormhole and implodes.

There’s not much more I can say about the story without revealing some “Crying Game”-grade spoilers. Effectively, though, the film accomplishes two things: It plays to the fears, stigmas, and ethical quandaries that arise with the prescription of uncertain psychiatric medications, then absolves itself of exploring whether any of them are founded.

The prime example of this failure deals with how psychiatric drugs are regulated. In one scene, Law’s Dr. Banks discovers a study done about the side effects of Ablixa, of which he had not been aware before prescribing. Later, he finds out through a TV talk show that other psych meds have had serious side effects that weren’t properly disclosed to docs and patients. The film even cites the real-life example of Paxil and its marketers obscuring the fact that the medication increased the risk of suicide in young people, which led to the FDA requiring a “black box” warning on the drug and other antidepressants in 2004.

But that’s about where the discussion ends. It’s a shame, because regulation of pharma seems as pertinent as ever: In December, a New York federal appeals court overturned a drug rep’s conviction for marketing unapproved, off-label uses for Xyrem, a narcolepsy medication, justifying the drug rep’s actions as free speech. As journalist Mina Kimes highlighted in a story explaining the decision, this means that pharmaceutical companies may care less about putting their products through rigorous—and costly—clinical trials.

According to Dr. Rona Hu, the medical director of Stanford Hospital’s acute psychiatric inpatient program, the film presents another conundrum: Its myopic focus on ostensibly scary meds (mostly lost in the train wreck that is the film’s second half) could potentially deter some people from seeking treatment for psychological problems. “I treat patients, and they come in with very serious symptoms,” Hu told me. “It’s often very difficult to get them to seek treatment or acknowledge the severity of the symptoms.”

Ultimately, the most painful side effect of “Side Effects” is that it treats the personal and societal implications of psychiatric medications as beside the point. Its true concern, apparently, is about the greed and materialism that motivate nearly all of its characters, including the “good” guys. This is the one constant in the film—and makes for a highly effective downer, without a doubt.

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate